<DOC>
	<DOCNO>NCT02816346</DOCNO>
	<brief_summary>Development S. sonnei human challenge model use newly manufacture lyophilize lot S. sonnei strain 53G ( Lot 1794 ) use future challenge strain S. sonnei vaccine candidate . An adaptable dosing plan use determine dose Shigella sonnei 53G induces primary outcome approximately 60 % subject .</brief_summary>
	<brief_title>Shigella Sonnei 53G Challenge</brief_title>
	<detailed_description />
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<criteria>1 . Male nonpregnant female 18 49 year age ( inclusive ) . 2 . General good health define ( ) significant medical illness , ( b ) clinically significant physical examination finding ( c ) screen laboratory value significantly outside normal limit test laboratory within 45 day challenge . 3 . Demonstrate comprehension protocol procedure knowledge study pass write examination ( pas grade ≥70 % ) day 1 . 4 . Willing sign inform consent form ( ICF ) . 5 . Willingness participate inpatient stay last 11 day outpatient followup last 6 month challenge . 6 . Willing smoke inpatient stay . 7 . Available planned followup visit . 8 . Negative serum pregnancy test screen negative urine pregnancy test day admission inpatient phase female subject childbearing potential . Females childbearing potential must agree use effective method birth control ( birth control pill , injection hormonal contraceptive , implant hormonal contraceptive , hormonal patch , IUD , sterilization hysterectomy tubal ligation , spermicidal product barrier method cervical sponge , diaphragm , condom ) within two month challenge entire study . Abstinence acceptable . A woman eligible monogamous vasectomized partner . 9 . Willing donate blood 6 month completion inpatient phase study . 10 . Willing refrain participation another investigational vaccine drug trial least completion 6 month followup safety call . 1 . Presence significant medical condition ( e.g . psychiatric condition , alcohol illicit drug abuse/dependency , gastrointestinal disease , peptic ulcer , symptom evidence active gastritis gastroesophageal reflux disease , inflammatory bowel disease ) , laboratory abnormality opinion investigator precludes participation study . 2 . Immunosuppressive illness IgA deficiency 3 . Positive serology result HIV , HBsAg , HCV , RPR ( syphilis ) antibody . 4 . Evidence inflammatory arthritis exam and/or HLAB27 positive . 5 . Family history inflammatory arthritis . 6 . Significant abnormality screen lab hematology serum chemistry , determine PI . 7 . Allergy fluoroquinolones trimethoprimsulfamethoxazole 8 . Fewer 3 stool per week 3 stool per day usual frequency . 9 . History diarrhea 2 week prior plan inpatient phase 10 . Use antibiotic 7 day receive challenge inoculum dose 11 . Use prescription and/or OTC medication contain Imodium , acetaminophen , aspirin , ibuprofen , nonsteroidal antiinflammatory drug , 48 hour prior investigational product administration 12 . Travel within two year prior dose country Shigella infection endemic . 13 . Use medication know affect immune function [ e.g. , oral steroid , parenteral steroid , highdose inhaled steroid ( &gt; 800 μg/day beclomethasone dipropionate equivalent others ) : nasal topical steroid allow ] within 30 day precede receipt challenge inoculum plan use active study period . 14 . Serologic evidence Shigella sonnei ( titer &gt; 1:2500 ) 15 . A positive urine test opiate . 16 . A chronic disease ( hypertension , hyperlipidemia anxiety/depression ) dose prescription medication stable least past 3 month . 17 . Scheduled and/or longterm use oral steroid , parenteral steroid , highdose inhaled steroid ( &gt; 800 μg/day beclomethasone dipropionate equivalent ) within precede 6 month ( Nasal , intraarticular , topical steroid allow ) 18 . Have immunocompromised household contact . 19 . A clinically significant abnormality physical examination , include systolic blood pressure &gt; 140 mm Hg diastolic blood pressure &gt; 90 mm Hg , rest pulse &gt; 100 beats/min &lt; 55 beats/min ( &lt; 50 beats/min condition athlete ) . 20 . Pregnant , nursing , plan become pregnant within 6 month receipt study product . 21 . In 4 week follow challenge , subject live daily contact elderly person age 70 year , diapered individual , person disability , child &lt; 2 year old , woman know pregnant nursing , anyone diminish immunity . This include contact home , school , daycare , nurse home , similar place . 22 . Work health care set , day care center , food handler 4 week follow challenge S. sonnei . 23 . Use investigational drug investigational vaccine within 60 day precede challenge , plan use 6 month receipt study agent . 24 . Have receive license , live vaccine within 28 day license inactivated vaccine within 14 day receive challenge inoculum . 25 . Inability comply inpatient rule regulation . 26 . Has condition , opinion Investigator , would jeopardize safety right participant would render subject unable comply protocol . 27 . Received blood blood product within past six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>shigella</keyword>
</DOC>